左乙拉西坦的药物基因组学与疗效预测研究进展

Progress in pharmacogenomics and efficacy prediction of levetiracetam

左乙拉西坦(LEV)是第二代广谱抗癫痫药,与其他抗癫痫药相比,具有独特的抗癫痫机制、良好的疗效及耐受性。随着LEV的广泛应用,其不良反应也越来越受到临床关注,尤其是精神相关不良反应。基因多态性可能是造成上述药物反应个体差异性的重要因素。本文以LEV药物基因组学相关的作用靶点、代谢、不良反应相关的遗传变异及疗效预测等研究进展进行综述,为临床实践中癫痫患者应用LEV个体化治疗提供决策,进而提高癫痫患者的生活质量,减轻癫痫患者的疾病负担。

Levetiracetam(LEV)is the second generation of broad-spectrum antiepileptic drugs.Compared with other antiepileptic drugs,LEV has unique antiepileptic mechanism,good efficacy and tolerance,and its target is synaptic vesicle protein 2A.With the widespread use of LEV,more and more adverse reactions have been reported,especially mental related adverse reactions.This paper reviewed the research progress of LEV pharmacogenomics related targets,metabolism,adverse reaction related genetic variation and efficacy prediction,so as to provide decision-making for the application of LEV individualized treatment in clinical practice,improve the quality of life of epileptic patients and reduce the disease burden of patients with epilepsy.